Vitamin D
Growth factor
OHSS
Ovary
VEGF
Vitamin
Journal
In vitro cellular & developmental biology. Animal
ISSN: 1543-706X
Titre abrégé: In Vitro Cell Dev Biol Anim
Pays: Germany
ID NLM: 9418515
Informations de publication
Date de publication:
04 Apr 2024
04 Apr 2024
Historique:
received:
28
01
2024
accepted:
13
03
2024
medline:
4
4
2024
pubmed:
4
4
2024
entrez:
4
4
2024
Statut:
aheadofprint
Résumé
It has been reported that the effective inhibition of vascular endothelial growth factor (VEGF) can prevent the progression of ovarian hyperstimulation syndrome (OHSS). The present study aimed to investigate the mechanism underlying the effect of vitamin D
Identifiants
pubmed: 38573397
doi: 10.1007/s11626-024-00898-z
pii: 10.1007/s11626-024-00898-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fujian Medical University
ID : 2020QH1294
Informations de copyright
© 2024. The Author(s).
Références
Burjiah AR, Sa’adi A, Widjiati W, (2022) Vitamin D inhibited endometriosis development in mice model through interleukin-17 modulation. Open Vet J 12:956–964. https://doi.org/10.5455/OVJ.2022.v12.i6.23
doi: 10.5455/OVJ.2022.v12.i6.23
pubmed: 36650872
pmcid: 9805767
Castillo JC, Haahr T, Martínez-Moya M, Humaidan P (2020) Gonadotropin-releasing hormone agonist ovulation trigger-beyond OHSS prevention. Ups J Med Sci 125:138–143. https://doi.org/10.1080/03009734.2020.1737599
doi: 10.1080/03009734.2020.1737599
pubmed: 32208810
pmcid: 7721031
Cheng JC, Fang L, Li Y et al (2020) Melatonin stimulates aromatase expression and estradiol production in human granulosa-lutein cells: relevance for high serum estradiol levels in patients with ovarian hyperstimulation syndrome. Exp Mol Med 52:1341–1350. https://doi.org/10.1038/s12276-020-00491-w
doi: 10.1038/s12276-020-00491-w
pubmed: 32855437
pmcid: 8080626
Da J, Yang Y, Dong R, Shen Y, Zha Y (2020) Therapeutic effect of 1,25(OH)2-vitamin D3 on fibrosis and angiogenesis of peritoneum induced by chlorhexidine. Biomed Pharmacother 129:110431. https://doi.org/10.1016/j.biopha.2020.110431
doi: 10.1016/j.biopha.2020.110431
pubmed: 32585450
Doni A, Garlanda C, Mantovani A (2016) Innate immunity, hemostasis and matrix remodeling: PTX3 as a link. Semin Immunol 28:570–577. https://doi.org/10.1016/j.smim.2016.10.012
doi: 10.1016/j.smim.2016.10.012
pubmed: 27881292
pmcid: 5414833
Fang L, Yu Y, Li Y, Wang S, He J, Zhang R, Sun YP (2019) Upregulation of AREG, EGFR, and HER2 contributes to increased VEGF expression in granulosa cells of patients with OHSS†. Biol Reprod 101:426–432. https://doi.org/10.1093/biolre/ioz091
doi: 10.1093/biolre/ioz091
pubmed: 31167229
Farkas B, Boldizsar F, Bohonyi N et al (2020) Comparative analysis of abdominal fluid cytokine levels in ovarian hyperstimulation syndrome (OHSS). J Ovarian Res 13:25. https://doi.org/10.1186/s13048-020-00624-9
doi: 10.1186/s13048-020-00624-9
pubmed: 32138790
pmcid: 7057507
Guzmán A, Hernández-Coronado CG, Gutiérrez CG, Rosales-Torres AM (2023) The vascular endothelial growth factor (VEGF) system as a key regulator of ovarian follicle angiogenesis and growth. Mol Reprod Dev 90:201–217. https://doi.org/10.1002/mrd.23683
doi: 10.1002/mrd.23683
pubmed: 36966489
Hortu I, Karadadas E, Ozceltik G, Tavmergen E, Tavmergen Goker EN, Yigitturk G, Erbas O (2021) Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model. Arch Gynecol Obstet 303:1099–1108. https://doi.org/10.1007/s00404-020-05855-1
doi: 10.1007/s00404-020-05855-1
pubmed: 33140116
Huang J, Mao Y, Li Q et al (2022) Kallistatin prevents ovarian hyperstimulation syndrome by regulating vascular leakage. J Cell Mol Med 26:4613–4623. https://doi.org/10.1111/jcmm.17491
doi: 10.1111/jcmm.17491
pubmed: 35866203
pmcid: 9357611
Irani M, Seifer DB, Grazi RV, Irani S, Rosenwaks Z, Tal R (2017) Vitamin D decreases serum VEGF correlating with clinical improvement in vitamin D-deficient women with PCOS: a randomized placebo-controlled trial. Nutrients 9. https://doi.org/10.3390/nu9040334
Korhonen K, Unkila-Kallio L, Alfthan H et al (2020) Plasma pentraxin 3 is higher in early ovarian hyperstimulation syndrome than in uncomplicated in vitro fertilization cycle of high-risk women. Arch Gynecol Obstet 301:1569–1578. https://doi.org/10.1007/s00404-020-05556-9
doi: 10.1007/s00404-020-05556-9
pubmed: 32372340
pmcid: 7246248
Li Y, Fang L, Yu Y, Shi H, Wang S, Guo Y, Sun Y (2019) Higher melatonin in the follicle fluid and MT2 expression in the granulosa cells contribute to the OHSS occurrence. Reprod Biol Endocrinol 17:37. https://doi.org/10.1186/s12958-019-0479-6
doi: 10.1186/s12958-019-0479-6
pubmed: 30979376
pmcid: 6461819
Luo J, Qi Q, Chen Y, Wang Y, Xie Q (2021) Effect of GnRH-antagonist, mifepristone and letrozole on preventing ovarian hyperstimulation syndrome in rat model. Reprod Biomed Online 42:291–300. https://doi.org/10.1016/j.rbmo.2020.10.006
doi: 10.1016/j.rbmo.2020.10.006
pubmed: 33249057
Mills G, Dahan MH (2022) Gonadotropin releasing hormone (GnRH) antagonist administration to decrease the risk of ovarian hyperstimulation syndrome in GNRH agonist cycles triggered with human chorionic gonadotropin. Arch Gynecol Obstet 306:1731–1737. https://doi.org/10.1007/s00404-022-06717-8
doi: 10.1007/s00404-022-06717-8
pubmed: 35932297
Rajkovic I, Wong R, Lemarchand E et al (2018) Pentraxin 3 promotes long-term cerebral blood flow recovery, angiogenesis, and neuronal survival after stroke. J Mol Med (berl) 96:1319–1332. https://doi.org/10.1007/s00109-018-1698-6
doi: 10.1007/s00109-018-1698-6
pubmed: 30315331
Şanlı C, Atılgan R, Kuloğlu T, Pala Ş, İlhan N (2023) The investigation of cholinergic receptor muscarinic 1 activity in the rat ovary with induced ovarian hyperstimulation. Turk J Obstet Gynecol 20:53–58. https://doi.org/10.4274/tjod.galenos.2023.75336
doi: 10.4274/tjod.galenos.2023.75336
pubmed: 36908094
pmcid: 10013087
Stravalaci M, Ferrara M, Pathak V et al (2021) The long pentraxin PTX3 as a new biomarker and pharmacological target in age-related macular degeneration and diabetic retinopathy. Front Pharmacol 12:811344. https://doi.org/10.3389/fphar.2021.811344
doi: 10.3389/fphar.2021.811344
pubmed: 35069222
Sun B, Ma Y, Li L et al (2020) Factors associated with ovarian hyperstimulation syndrome (OHSS) severity in women with polycystic ovary syndrome undergoing IVF/ICSI. Front Endocrinol (lausanne) 11:615957. https://doi.org/10.3389/fendo.2020.615957
doi: 10.3389/fendo.2020.615957
pubmed: 33542709
Timmons D, Montrief T, Koyfman A, Long B (2019) Ovarian hyperstimulation syndrome: a review for emergency clinicians. Am J Emerg Med 37:1577–1584. https://doi.org/10.1016/j.ajem.2019.05.018
doi: 10.1016/j.ajem.2019.05.018
pubmed: 31097257
Turan GA, Eskicioglu F, Sivrikoz ON et al (2015) Prophylactic vitamin D supplementation in ovarian hyperstimulation syndrome: an animal study. Arch Gynecol Obstet 292:421–427. https://doi.org/10.1007/s00404-015-3625-1
doi: 10.1007/s00404-015-3625-1
pubmed: 25618750
Uhlén M, Fagerberg L, Hallström BM et al (2015) Proteomics. Tissue-based map of the human proteome. Science 347:1260419. https://doi.org/10.1126/science.1260419
doi: 10.1126/science.1260419
pubmed: 25613900
Wang B, Wang J, Liu Y, Wang L, Du M, Zhang Z, Guan Y (2021) sRAGE downregulates the VEGF expression in OHSS ovarian granulosa cells. Gynecol Endocrinol 37:836–840. https://doi.org/10.1080/09513590.2021.1942453
doi: 10.1080/09513590.2021.1942453
pubmed: 34223781
Wu X, Hu W, Lu L et al (2019) Repurposing vitamin D for treatment of human malignancies via targeting tumor microenvironment. Acta Pharm Sin B 9:203–219. https://doi.org/10.1016/j.apsb.2018.09.002
doi: 10.1016/j.apsb.2018.09.002
pubmed: 30972274
Yan B, Wu B, Wang ZQ, Wei Y, Ni YL (2023) Peripheral blood transcriptome analysis of patients with ovarian hyperstimulation syndrome through high-throughput sequencing. Reprod Dev Med 7:115–121. https://doi.org/10.1097/rd9.0000000000000058
doi: 10.1097/rd9.0000000000000058
pubmed: 37519480
pmcid: 10241322
Zhang J, Huang J, He X et al (2022) Ginkgo biloba extract 761 reduces vascular permeability of the ovary and improves the symptom of ovarian hyperstimulation syndrome in a rat model. Gynecol Endocrinol 38:318–323. https://doi.org/10.1080/09513590.2022.2034147
doi: 10.1080/09513590.2022.2034147
pubmed: 35285758